Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP

Modern Pathology

Volumn 20, Issue 1, 2007, Pages 15-22

  Ogino, Shuji ^a,b,c   Kawasaki, Takako ^b   Kirkner, Gregory J ^a   Yamaji, Taiki ^d   Loda, Massimo ^a,b,c   Fuchs, Charles S ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CIMP; Colon cancer; Cyclin dependent kinase inhibitor; MSI; p27; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P16; PROTEIN P53;

ARTICLE; BRAF GENE; CACNA1G GENE; CDKN2A GENE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND METHYLATOR PHENOTYPE; CRABP1 GENE; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MLH1 GENE; NEUROG1 GENE; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE; WILD TYPE;

CELL NUCLEUS; COHORT STUDIES; COLORECTAL NEOPLASMS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; REGISTRIES; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 33845702458     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800709     Document Type: Article

References (46)

1. Macaluso M, Montanari M, Cinti C, et al. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol 2005;32:452-457.
2. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
3. Carrano AC, Eytan E, Hershko A, et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-199.
4. Tsvetkov LM, Yeh KH, Lee SJ, et al. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-664.
5. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
6. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23:4776-4789.
7. Chetty R. p27 Protein and cancers of the gastrointestinal tract and liver: an overview. J Clin Gastroenterol 2003;37:23-27.
8. Thomas GV, Szigeti K, Murphy M, et al. Downregulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998;153:681-687.
9. Xu XL, Yu J, Zhang HY, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004;10:3441-3454.
10. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-993.
11. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14(Spec No 1):R65-R76.
12. Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 2000;97:710-715.
13. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
14. van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002;51:797-802.
15. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122:1376-1387.
16. Kambara T, Simms LA, Whitehall VLJ, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137-1144.
17. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004;22:4584-4594.
18. Samowitz W, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-845.
19. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-1006.
20. Ogino S, Odze RD, kawasaki T, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006;30:1175-1183.
21. Goel A, Li MS, Nagasaka T, et al. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology 2006;130:1950-1961.
22. Ogino S, kawasaki T, Kirkner GJ, et al. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006;210:147-154.
23. Edmonston TB, Cuesta KH, Burkholder S, et al. Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Hum Pathol 2000;31:1506-1514.
24. Grady WM, Willis JE, Trobridge P, et al. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer 2006;118:600-608.
25. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59:2302-2306.
26. Eads CA, Danenberg KD, Kawakami K, et al. Methy-Light: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
27. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-3813.
28. Ogino S, kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
29. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5:388-396.
30. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a Prospective Study. J Natl Cancer Inst 2005;97:1688-1694.
31. Ogino S, Brahmandam M, kawasaki T, et al. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8:458-464.
32. Ogino S, Brahmandam M, kawasaki T, et al. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 2006;19:1083-1090.
33. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-421.
34. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68.
35. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-3418.
36. Ogino S, kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-588.
37. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6656.
38. Muller HM, Millinger S, Fiegl H, et al. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem 2004;50:2171-2173.
39. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and the field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-1338.
40. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst 2005;97:1317-1319.
41. Baas IO, Mulder JW, Offerhaus GJ, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
42. Curtin K, Slattery ML, Holubkov R, et al. p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol 2004;12:380-386.
43. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 2006;208:1-6.
44. Palmqvist R, Stenling R, Oberg A, et al. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18-23.
45. Noguchi T, Kikuchi R, Ono K, et al. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol Rep 2003;10:827-831.
46. Manne U, Jhala NC, Jones J, et al. Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage. Clin Cancer Res 2004;10:1743-1752.